Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET by Greenall, Sameer A. et al.
Non-Agonistic Bivalent Antibodies That Promote c-MET
Degradation and Inhibit Tumor Growth and Others
Specific for Tumor Related c-MET
Sameer A. Greenall
1¤, Ermanno Gherardi
2, Zhanqi Liu
3, Jacqueline F. Donoghue
1, Angela A. Vitali
3,
Qian Li
1, Roger Murphy
3, Luisa Iamele
2, Andrew M. Scott
3., Terrance G. Johns
1*
.
1Oncogenic Signaling Laboratory, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia, 2Medical Research Council Centre, Cambridge,
United Kingdom, 3Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
Abstract
The c-MET receptor has a function in many human cancers and is a proven therapeutic target. Generating antagonistic or
therapeutic monoclonal antibodies (mAbs) targeting c-MET has been difficult because bivalent, intact anti-Met antibodies
frequently display agonistic activity, necessitating the use of monovalent antibody fragments for therapy. By using a novel
strategy that included immunizing with cells expressing c-MET, we obtained a range of mAbs. These c-MET mAbs were
tested for binding specificity and anti-tumor activity using a range of cell-based techniques and in silico modeling. The LMH
80 antibody bound an epitope, contained in the small cysteine-rich domain of c-MET (amino acids 519–561), that was
preferentially exposed on the c-MET precursor. Since the c-MET precursor is only expressed on the surface of cancer cells
and not normal cells, this antibody is potentially tumor specific. An interesting subset of our antibodies displayed profound
activities on c-MET internalization and degradation. LMH 87, an antibody binding the loop connecting strands 3d and 4a of
the 7-bladed b-propeller domain of c-MET, displayed no intrinsic agonistic activity but promoted receptor internalization
and degradation. LMH 87 inhibited HGF/SF-induced migration of SK-OV-3 ovarian carcinoma cells, the proliferation of A549
lung cancer cells and the growth of human U87MG glioma cells in a mouse xenograft model. These results indicate that c-
MET antibodies targeting epitopes controlling receptor internalization and degradation provide new ways of controlling c-
MET expression and activity and may enable the therapeutic targeting of c-MET by intact, bivalent antibodies.
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Introduction
C-MET, the receptor for hepatocyte growth factor/scatter
factor (HGF/SF), is produced as a 170 kDa precursor protein
(p170 c-MET) which is subsequently cleaved by the pro-protein
convertase furin to produce a disulphide-linked heterodimeric
receptor tyrosine kinase (RTK). The mature receptor consists of
an extracellular 50 kDa a-chain and an extracellular/intracellular
145 kDa b-chain that contains the TK domain. The a-chain and
the N-terminal part of the b-chain associate to form a 7-bladed b-
propeller, the SEMA domain, which contains the main binding
site for HGF/SF [1]. Upon HGF/SF binding, c-MET homo-
dimerizes leading to activation of its TK domain, as well as
autophosphorylation of several tyrosine residues including the C-
terminal residues Y1349 and Y1356. Phosphorylated Y1349 and
Y1356 form a multi-substrate docking site capable of binding
several adaptor proteins to initiate downstream signaling associ-
ated with the PI3K/Akt and Ras/MAPK pathways [1,2].
The HGF/SF:c-MET signaling axis has an important role in
the initiation and progression of several aggressive cancers
including glioblastoma multiforme (GBM) [3,4,5]. As such, c-
MET has been intensely investigated as a therapeutic target with
several classes of agents being developed as therapeutics, including
small molecular weight tyrosine kinase inhibitors (TKIs), which
prevent the activation of c-MET by acting as ATP-binding
competitors. These TKIs have been shown to have anti-tumor
activity in both in vitro and in vivo models (reviewed in [2,6]), with
several candidates currently being evaluated clinically. Monoclo-
nal antibodies (mAbs) directed to c-MET or HGF/SF represent an
alternative class of therapeutics that is attracting considerable
interest. Treatment of U87MG GBM xenografts with Rilotumu-
mab, a fully human neutralizing antibody directed to HGF/SF,
significantly inhibited tumor growth in mouse xenograft models
[7,8]. Another anti-HGF/SF mAb, TAK-701, effectively reversed
c-MET-induced gefitinib resistance in several in vitro and in vivo
models of NSCLC [9].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34658Antagonistic mAbs directed to c-MET have been difficult to
generate as many bivalent antibodies appear to function as
agonists. As such, the c-MET antibody in the most advanced
clinical trial (MetMAb or Onartuzumab) is a monovalent
recombinant antibody fragment derived from an anti-c-MET
antibody with agonistic activity [10,11]. MetMAb appears to
function as a classic receptor antagonist by competing with HGF/
SF for binding to c-MET [10,11]. DN-30 is an anti-c-MET
antibody with partial agonistic activity [12] that also promotes
receptor down-regulation. DN30 was able to inhibit the growth of
a gastric cancer xenograft model through stimulating c-MET
shedding [13,14]. Once more, conversion to a monovalent format
proved necessary in order to abolish the agonistic activity [15].
Using the human c-MET SEMA domain and live c-MET
expressing cells for immunization of mice, we generated a panel of
mAbs directed to c-MET which displayed a range of novel
properties. These mAbs were assessed biochemically and biolog-
ically for their activity on c-MET signalling. The antibodies
generated fell into three categories: 1) agonist antibodies as
previously reported; 2) a series of antibodies that only bind the c-
MET precursor and therefore may be tumor-specific; and, 3)
bivalent antibodies that induce c-MET degradation and inhibit
tumor growth.
Results
Characterization of the LMH anti-c-MET antibody panel
We characterized in detail 10 antibodies (designated LMH) that
bound c-MET on the surface of A549 lung cancer cells as
determined by FACS (Figure 1A and Table 1). To establish which
c-MET chain the antibodies bound, c-MET was immunoprecip-
itated (IPed) with a commercial pan-c-MET antibody and
immunoblotted (IB) with the individual LMH antibodies. The
antibody panel contained both a-chain and b-chain binders
(Figure 1B and Table 1). Blots for LMH 80 showed it weakly
bound the 145 kDa b-chain of c-MET, while LMH 82, LMH 84
and LMH 87 all bound the 170 kDa c-MET precursor (p170 c-
MET) and the 50 kDa a-chain of c-MET. Most LMH antibodies
were also able to IP c-MET from A549 lysates (Figure 1C and
Table 1). Interestingly, LMH 80, LMH 81 and LMH 82 appeared
only to IP the p170 c-MET (Figure 1C, left panel). The remaining
Figure 1. Representative data showing characterization of
selected LMH antibodies. (A) flow cytometry analysis showing that
LMH 85 and LMH 87 bind surface c-MET expressed on A549 cells. (B)
western blots of representative LMH antibodies. c-MET was IPed with
LMH 85 and membranes probed with indicated antibodies. The
commercial 25H2 recognized the 170 kDa c-MET precursor (p170 c-
MET; contains both a and b-chain) and the c-MET b-chain. Using this
technique, LMH 80 only weakly bound the b-chain, while LMH 82, 84
and 87 bound p170 c-MET and a-chain. (C) IP with selected LMH
antibodies. Following IP with different LMH antibodies, membranes
were blotted with mAb 25H2. Antibodies shown were all capable of IP
but LMH 80, LMH 81 and LMH 82 appeared specific for p170 c-MET
using this technique. (D) biochemical activity of selected LMH
antibodies. A459 cells were treated with antibody alone or antibody
in the presence of HGF/SF and WCL were probed for total c-MET (upper
panels) or phosphorylated c-MET (Y1234/Y1235) (lower panels). LMH 85
stimulated c-MET phosphorylation, whilst LMH 86 and LMH 87 did not.
LMH 86 was unable to block HGF/SF stimulated c-MET phosphorylation.
(E) effect of selected LMH antibodies on cell migration. Antibodies were
tested for their ability to induce cell migration in SK-OV-3 cells. LMH 85
stimulated cell migration while LMH 87 had no effect (upper panel).
Differing concentrations of LMH 87 were mixed with 3610
210 M HGF/
SF to determine if it inhibited the HGF/SF induced migration of SK-OV-3
cells. LMH 87 substantially inhibited the migratory activity stimulated by
HGF/SF (lower panel). Data in both graphs are presented as percentage
migration versus 3610
210 M HGF/SF 6 SD. A full summary of all LMH
antibodies is contained in Table 1.
doi:10.1371/journal.pone.0034658.g001
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LMH 83 that did not IP any c-MET, bound both mature and
p170 c-MET.
As part of our initial screen, all our antibodies were screened
biochemically for agonist and antagonist properties using A549
lung cancer cells (Figures 1D–E and Table 1). Incubation of A549
cells with the antibodies in the absence of HGF/SF showed that
LMH 85 had agonistic activity (Figure 1D, bottom panel), while
other antibodies failed to activate c-MET (Table 1). None of the
antibodies were able to block short-term, ligand-induced activa-
tion of c-MET (see Figure 1D, bottom panel for representative results
with LMH 86). A sub-set of the LMH antibodies were
subsequently screened for biological activity in SK-OV-3 ovarian
cancer cells. LMH 85 was able to induce migration in SK-OV-3
cells (Figure 1E, top panel), consistent with its ability to induce
phosphorylation of c-MET (Figure 1D). In contrast LMH 87 had
no effect on cell migration (Figure 1E, top panel), consistent with its
lack of biochemical agonist activity (Figure 1D). LMH 87 was able
to inhibit .75% of HGF/SF-induced migration of SK-OV3 cells
at concentrations $3610
28 M (Figure 1E, bottom panel, p,0.05).
LMH 88 inhibited HGF/SF-induced SK-OV-3 migration to a
similar extent to that observed for LMH 87 (Figure S1B). The
biological/biochemical properties of all antibodies, including the
binding affinity determined by BIAcore, are summarized in
Table 1.
Single chain variable fragments, made from the agonist
LMH 85, are able to block HGF binding to c-MET
Single domain antibodies made from anti-c-MET agonist mAbs
are sometimes effective in antagonizing HGF/SF induced
stimulation of c-MET both in vitro and in vivo [11]. Therefore we
converted the agonist antibody LMH 85, as well as LMH 87, into
a single chain variable fragment (scFv) and tested whether they
were able to function as a c-MET antagonist. scFv 85 decreased
HGF/SF stimulation of c-MET as determined by IB for
phosphorylated receptor (Figure 2). In contrast, scFv 87 was
unable to block HGF/SF stimulation of c-MET, with levels of
phosphorylated c-MET similar to that in the HGF/SF control
(Figure 2). Thus, when the agonist mAb LMH 85 was converted to
scFv format, it was able to function as a c-MET antagonist.
Mapping the epitopes of the LMH antibody panel
To determine the fine epitopes for LMH 80–89, we conducted
an analysis with overlapping peptides encompassing the entire c-
MET SEMA domain. Most antibodies strongly bound some of the
linear peptides with examples of the ELISA results shown in
Figures 3A–D. These reactive peptide sequences were then aligned
Table 1. Summary of results for a series of biochemical analyses on the properties of the LMH monoclonal antibody panel.
Antibody
ELISA
Positive
Flow Cytometry
Positive Immunoblot IP
Binding
Affinity (KD)
HGF/SF
Antagonist
a
c-MET
Agonist
a
Antagonist of
HGF/SF- Induced
Cell Migration
b
Induces Cell
Migration
b
LMH 80 Yes Yes Yes, b-chain Yes, c-MET
precursor
34 nM No No n.d. n.d.
LMH 81 Yes Yes No Yes, c-MET
precursor
12 nM No No n.d. n.d.
LMH 82 Yes Yes Yes, a-chain Yes, c-MET
precursor
n.d. No No n.d. n.d.
LMH 83 Yes Yes No No 26 nM No No n.d. n.d.
LMH 84 Yes Yes Yes, a-chain Yes 36 nM No No n.d. n.d.
LMH 85 Yes Yes No Yes n.d. No Yes No Yes
LMH 86 Yes Yes Yes, a-chain Yes n.d. No No No No
LMH 87 Yes Yes Yes, a-chain Yes 2.6 nM No No Yes No
LMH 88 Yes Yes Yes, a-chain Yes 76 nM No No Yes No
LMH 89 Yes Yes Yes, a-chain Yes 31 nM No No Yes No
n.d.=not determined; IP=immunoprecipitation; HGF/SF=hepatocyte growth factor/scatter factor.
aassays performed using A549 lung adenocarcinoma cells.
bassays performed using SK-OV-3 ovarian carcinoma cells.
doi:10.1371/journal.pone.0034658.t001
Figure 2. Antagonist activity of single chain variable frag-
ments. LMH 85 and LMH 87 were converted into scFv format and
tested for their ability to block HGF/SF stimulation of the c-MET
receptor. A549 cells were treated with either scFv 85 or scFv 87 and
then HGF/SF added. A vehicle control without HGF/SF was included.
Whole cell lysates were then probed for total c-MET (upper panel),
phosphorylated c-MET (Tyr1234/1235; middle panel) and pan-actin to
control for loading (bottom panel). The phosphorylated c-MET blot
shows that scFv 85, but not scFv 87, inhibited HGF/SF stimulation of c-
MET.
doi:10.1371/journal.pone.0034658.g002
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34658Figure 3. Fine epitope mapping of the LMH antibodies. Antibody reactivity against a panel of overlapping biotinylated peptides representing
the c-MET SEMA domain was determined by ELISA. The data shows mean absorbance for selected peptides and the epitope sequences for (A) LMH
80; (B) LMH 82; (C) LMH 84 and (D) LMH 87. (E) epitopes were mapped on to the 3D structure of MET567 incorporating the SEMA domain and
cysteine-rich domain (CRD). The areas of the domain corresponding to the a- and b-chains are shown in grey and light blue respectively and the two
views are obtained through a 180u rotation along the y axis. Dark blue=LMH 87 (and LMH 86, 88, 89), pink=LMH 82, magenta=LMH 84 and
yellow=LMH 80 (and LMH 81). The figure was drawn using PDB accession 1SHY with PYMOL (DeLano Scientific, San Carlos, CA, USA).
doi:10.1371/journal.pone.0034658.g003
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Epitopes were then highlighted within the SEMA domain and
cysteine-rich domain (CRD) of MET567 (Figure 3E). LMH 83
and LMH 85 did not bind any linear peptide, indicating that their
epitopes are conformational in nature, an observation consistent
with the results of IB analyses (Table 1). LMH 86–89 all mapped
to an identical DVLPEFRDSY epitope (aa 236–245) within the c-
MET a-chain which corresponds to the loop connecting strands
3d-4a on the top side of the c-MET b-propeller (dark blue in
Figure 3E, left panel). Several antibodies bound to the bottom side
of the b-propeller domain including LMH 82 and LMH 84, which
mapped to the separate epitopes VVDTYYDDQL (aa 120–129)
and VRRLKETKDGFMFLT (aa 215–229), respectively. Both
these epitopes are within the c-MET a-chain and contain the loops
connecting strands 2a-2b (LMH 82) and strands 3c-3d (LMH 84)
(pink and magenta respectively in Figure 3E, right panel). Finally,
LMH 80 mapped to a sequence (RHFQSCSQCLSAPPFVQ-
CGWC, aa 521–535) within the CRD of c-MET b-chain that
contains an 11 amino acid long a-helix (yellow in Figure 3E, right
panel).
Docking of LMH 87 onto c-MET
The sequence of the VH and VL chains of LMH 85 and LMH
87 with the predicted amino acid translations are shown in
Figure 4A. In order to highlight the binding site of LMH 87, a 3D
model of its variable domain was generated (Figure 4B) and the
corresponding scFv docked with its epitope within c-MET; an area
that includes and surrounds the loop connecting strands 3d-4a
(Figure 4C). The binding of LMH 87 was also compared with the
binding site of the serine proteinase homology domain (SPHD) of
HGF/SF that has been defined crystallographically (Figure 4C)
[16]. LMH 87 binds the a-chain of the c-MET b-propeller on its
top and side faces, whereas the SPHD domain of HGF/SF binds
the a-chain on the bottom face.
LMH 87 down-regulates total c-MET leading to anti-
tumor activity
The partial c-MET agonist mAb DN-30 is able to down-
regulate total c-MET surface receptor by promoting receptor
shedding [13]. Therefore, we tested LMH 87 for its ability to
down-regulate c-MET in A549 lung cancer cells by treating them
with antibody for 8 or 24 h. LMH 87 was able to down-regulate
cell surface c-MET in A549 cells (Figure 5A, upper blot) by 40% as
determined by densitometry (Figure 5A, bar graph) and total cellular
c-MET by a similar percentage (Figure 5A, lower blot and
Figure 5A, bar graph). LMH 87 also reduced total c-MET by
50% in U87MG glioma cells (Figure 5B), as determined by
densitometry (Figure 5B, bar graph). LMH 86, LMH 88 and LMH
89 bind the same core epitope as LMH 87 but LMH 88 was the
only other antibody which reduced c-MET levels; like LMH 87,
down-regulation was sustained for at least 24 h (Figure S1A).
To examine this further, the ability of LMH 87 to induce
internalization of c-MET was analyzed using confocal microscopy
(Figure 5C; bottom panels). The LMH 85 antibody (Figure 5C, top
panels) was included as a positive control for both staining and
internalization. The staining for both antibodies was membrane
bound, focal and punctate at 0 min, with LMH 85 demonstrating
more robust staining than LMH 87. Both antibodies showed
internalization at 37uC following incubation for 30 min and
60 min; with diffuse cytoplasmic and perinuclear staining observed
along with a loss of peripheral membrane staining. Pre-treatment
of A549 with TAPI-2, an inhibitor ofADAM-10, an enzyme which
initiates presenilin-dependent regulated intramembrane proteoly-
sis (PS-RIP) of c-MET after DN-30 treatment [14], had no effect
on LMH 87-induced c-MET down-regulation (Figure S2). This
demonstrates that LMH 87 induces c-MET down-regulation and
degradation through receptor internalization and not PS-RIP.
To see if this down-regulation had any functional consequence,
in addition to its ability to prevent cell migration (Figure 1E), we
investigated the effect of LMH 87 treatment on A549 growth using
xCELLigence analysis. Treatment of A549 cells with LMH 87
inhibited cellular growth as depicted by the decrease in normalized
cell indices for the 50 and 100 mg/ml treatments at all time points
(Figure 5D, p,0.05). U87MG glioma cells are dependent on the
HGF/SF:c-MET signaling axis for in vivo growth [8]. Therefore
we tested if the LMH 87 antibody had anti-tumor activity against
well established U87MG xenografts. After only three injections of
1 mg LMH 87, tumor growth was significantly inhibited at days
Figure 4. Docking of LMH 87 to c-MET. (A) predicted amino acid
sequences of LMH 85 and LMH 87 VH and VL domains. (B) 3D model of
the VH and VL domains of LMH87 (modeled as a scFv). The
complementarity determining regions (CDR) of the VH and VL domains
are shown in red and blue respectively. Framework regions are shown
in grey. (C) binding locations within MET567 (grey) of the serine-
protease homology domain (SPHD) of HGF/SF (yellow) (PDB accession
1SHY) and the scFv LMH 87 (red). The location of the latter was
obtained by docking the model of the LMH 87 scFv onto its epitope
(blue spheres). The figure was drawn with PYMOL.
doi:10.1371/journal.pone.0034658.g004
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(Figure 5E, p,0.05). Hence, LMH 87 is able to inhibit U87MG
glioma growth in vivo.
LMH 80 binds cell surface precursor c-MET and is not
internalized
Our initial experiments suggested that LMH 80, LMH 81 and
LMH 82 only bound p170 c-MET (Figure 1C). To evaluate this
further we examined these antibodies by IP in A549 lung cancer
cells and LoVo colon cancer cells, the latter only expressing the
p170 c-MET due to intrinsic defects in c-MET post-translational
processing [17]. LMH 80,LMH81 and LMH 82 specifically bound
thep170c-METinLoVo(Figure6A,toppanel)andA549(Figure6A,
lower panel) cells. While the three antibodies bound all the p170 c-
MET in A549 cells, they only IPed a subset of p170 c-MET
expressed in LoVo cells. The p170 c-MET was observed on the
surface of three different cancer cell lines (A549, LoVo and
U87MG) as determined by FACS using all three antibodies (Figure
S3). We then tested if LMH 80 is internalized after binding to LoVo
and A549 cells by confocal microscopy (Figure 6B). The pattern of
staining in both cell lines was focal and punctate. LMH 80 was
retained on the cell surface and not internalized for the entire
60 min time course, as illustrated by the lack of cytoplasmic staining
in both LoVo (Figure 6B, upper panels) and A549 (Figure 6B, lower
panels) cells. Hence, LMH 80 is able to bind p170 c-MET on the
surface of live cells but is not rapidly internalized.
Discussion
Our investigations have confirmed that anti-c-MET antibodies
with receptor antagonistic activity can be generated by converting
intact and bivalent antibodies to a monovalent format, a strategy
employed in order to generate the MetMAb antibody [10,11].
This approach also proved necessary in order to remove the
partial agonistic activity of the DN-30 antibody [15].
More importantly, the data presented here highlights two novel
classes of c-MET-targeting antibodies. The first is the generation of
three antibodies (LMH 80–82) that specifically recognize the
Figure 5. LMH 87 down-regulates surface c-MET and inhibits
tumor cell growth. (A) c-MET was IPed using anti-c-MET antibody
coupled to agarose beads from A549 lung cancer cells treated with LMH
87 and then cell surface biotinylated. Cell surface c-MET (upper blot) and
total c-MET (lower blot) levels were determined by IB as detailed in the
Materials & Methods. Bar graphs show quantification by densitometry
6 SEM. IRR=irrelevant antibody. (B) total c-MET remaining in U87MG
glioma cells following incubation with LMH 87. Bar graph shows
quantification by densitometry 6 SEM. Both (A) and (B) are
representative blots of repeated experiments. (C) LMH 85 and LMH
87 are internalized following engagement of the c-MET receptor. A549
cells were bound with LMH 85 (top panels) or LMH 87 (bottom panels)
followed by AF488- labeled secondary antibody at 4uC. Internalization
was induced with addition of media at 37uC. Significant internalization
of both antibodies was observed at 30 min and 60 min as indicated by
relocation of the fluorescent signal from the membrane to diffuse
cytoplasmic and perinuclear locations. Scale bar=10 mm. (D) xCELLi-
gence analysis of A549 cells treated with LMH 87. A549 cells were
treated with vehicle or different concentrations of LMH 87. Data is
presented as the cell index normalized to 21 h 6 SEM, the time point
when antibody was added. Both the 50 and 100 mg/ml treatments
caused a significant decrease (p,0.05) in cell index compared to vehicle
control. (E) inhibition of U87MG xenograft growth after LMH 87
administration. Mice were implanted with U87MG cells and injected
three times (days 7, 10 and 12) with 1 mg of LMH 87 or vehicle. Data is
presented as the mean tumor size in mm
3 6 SEM. LMH 87 significantly
inhibited tumor growth at day 12 (p=0.014) and day 14 (p=0.03).
doi:10.1371/journal.pone.0034658.g005
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epitopes recognized by these antibodies overlaps with the furin
cleavage site itself (i.e. the loop connecting strands 4d and 5a). LMH
80 and LMH 81 bind the a-helix of the CRD while LMH 82 binds
the loop connecting strands 2a-2b on the bottom face of the MET b-
propeller domain (Figure 3E). This information, and the fact that
these antibodies fail to bind mature c-MET by IP, strongly suggest
that furin cleavage of the c-MET precursor is accompanied by a
major conformational change. Using LMH 80 and non-permeating
immunofluorescence, we could definitively establish that p170 c-
METis expressed on cell surface ofhuman cancercells,in agreement
with previous studies in human SkHep1 and LoVo cell lines
[17,18,19]. Additionally, there is convincing evidence from murine
derived cancer cells that p170 c-MET is exposed at the cell surface,
and can be activated by HGF [20,21,22,23,24]. Significantly, non-
permeating analyses of primary rat hepatocytes suggested that p170
c-MET was unavailable for
125I-HGF/SF binding at the cell surface
[25]. The lack of p170 c-MET on the surface of normal cells strongly
suggests that its cell surface localization is specific for cancerous cells.
The punctate c-MET staining described here for LMH 85 most likely
represents non-covalent clusters of c-MET on the cell surface as
reported previously [26]. As this pattern was also observed for LMH
80, it indicates that p170 c-MET is probably contained within these
non-covalent clusters on the cell surface. LMH 80–82 may be useful
for targeting radiotherapeutic and chemotherapeutic agents to
tumors while preventing toxic exposure to normal tissues such as
liver. Furthermore, as nanoparticle technology develops, these
antibodies could be extremelyuseful toolsfor promoting the retention
of such particles within the tumor mass.
Thesecondnovel class ofantibody(LMH87 and LMH 88)isone
that promotes c-MET internalization and degradation and/or
interferes with receptor recycling to the cell surface (Figure 5A–C).
Alterations of RTK degradation and trafficking have emerged in
recent years as common and important features of tumor cells as
well as a rational target for therapeutic intervention [27]. Binding of
the LMH 87 and LMH 88 antibodies to an epitope in the a-chain
portion of the c-MET b-propeller promoted receptor degradation
independent of HGF/SF, leading to reduced levels of surface c-
MET in tumor cells. An initial animal experiment showed that
LMH 87 inhibited the growth of U87MG xenografts, confirming
that this mAb was effective in vivo even in the presence of autocrine
HGF/SF. The LMH 87 epitope is distinct from the HGF/SF
binding site, suggesting that the intact, bivalent form of this mAb
should lack agonistic activity; a hypothesis we confirmed experi-
mentally. Therapeutic inhibition of c-MET with intact, bivalent
LMH 87 would have clear advantages over the Fab or scFv formats
in terms of stability, half-life and the potential to mediate immune-
effector functions. LMH 87’s partial antagonistic activity may be
advantageous when used in combination with other targeted
therapies, especially those targeting EGFR, as it may improve the
therapeutic window without significantly increasing toxicity; a
potential problem when combining such agents.
The established role of c-MET and HGF/SF in the initiation and
progression of a variety of human cancers [1] has stimulated an
extraordinary effort into the development of c-MET specific TKIs,
with many of these currently under investigation in patients [28].
However, the potential for off-target effects and/or the emergenceof
resistant populations of tumor cells have already been observed.
Thus, despite the difficulties encountered, the drive to develop anti-
HGF/SF and anti-c-MET targeted mAbs has a solid and rational
foundation[29,30,31].Weexpectthatthetwonovelclassesofanti-c-
MET antibodies described here (LMH 80–82 and LMH 87–88) are
potential therapeutic candidates for the treatment of human cancer.
Materials and Methods
Cells lines and antibodies
The A549, U87MG, LoVo and SK-OV-3 cell lines were
obtained from the American Type Culture Collection at low
Figure 6. LMH 80, 81 and 82 bind specifically to cell surface
p170 c-MET precursor. (A) LMH 80, 81 and 82 only precipitate the
p170 c-MET precursor. c-MET was IPed from LoVo cells (top panel)o r
A549 cells (bottom panel) using LMH 80, 81, 82 and LMH 85 and probed
for total c-MET. A single 170 kDa band was visible in the LMH 80, 81 and
82 lanes, but not the 145 kDa b-chain. The 145 kDa b-chain was clearly
present following IP with LMH 85. (B) LMH 80 binds p170 c-MET on the
cell surface but is not internalized. Alexa-Fluor 488-labeled LMH 80 was
bound to LoVo (left panels) and A549 (right panels) cells at 4uCt o
prevent internalization. Warm medium was added to initiate internal-
ization and cells analyzed by confocal microscopy; no significant
internalization was observed. A labeled LMH 85 positive control and
labeled irrelevant isotype control antibody were included at 0 min.
doi:10.1371/journal.pone.0034658.g006
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[3,8,32,33]. Total c-MET antibodies included Met (25H2) (Cell
Signaling Technology, Danvers, MA) and Met (c-MET) (Abcam,
Cambridge, UK) whilst the phosphorylated c-MET antibody was
phospho-Met (3D7) (Tyr1234/1235) (Cell Signaling Technology).
Pan actin antibody was Ab-5 (ACTN05) (Thermo Fisher
Scientific, Fremont, CA).
Hybridoma and antibody production
BALB/c mice were immunized four times by i.p. injection at 4-
week intervals with 2610
6 lysed A549 cells, or c-MET antigen, in
incomplete Freund’s adjuvant (Sigma) following an initial
immunisation in complete Freund’s adjuvant (Sigma). Spleen cells
were fused with SP2/0 myeloma cells and clonal supernatants
were screened by ELISA for c-MET reactivity. Antibody was
purified using protein-A affinity chromatography.
Single chain variable fragment production
BL21.DE3* E.coli were transformed with pRSET vector
containing the scFv 85 and scFv 87 sequence. After IPTG
induction, cell pellets were solublized in 8M urea buffer and
purified using Ni-NTA columns. Protein was eluted using a
gradient of urea buffer containing increasing concentrations of
imidazole. Pooled pure fractions were dialysed with buffer
containing 500 mM sodium salt, 1 mM DTT and increasing
glycerol/decreasing urea concentrations. The final dialysis was in
PBS/5% glycerol.
Epitope mapping
A PepSet
TM Peptide library spanning amino acids 1–567 of the
c-MET SEMA domain was synthesized (Mimotopes, Clayton,
Australia). The library consisted of N-terminally biotinylated, 20-
mer peptides, overlapping by 15 amino acids and pre-absorbed
onto 96-well streptavidin coated plates. LMH antibodies 80 to 89
were added to determine their reactivity against each single
peptide using standard ELISA.
Protein modeling and docking
The sequences of the VH and Vk segments of mAb LMH 87
were assembled as scFv’s and used for homology modeling using
the 3D-Jigsaw server [34]. Models were evaluated using the
Ramachandran plot and VERIFY-3D [35] and used for protein-
protein docking using the FireDock server [36]. Docking solutions
were inspected visually and protein interfaces analyzed using the
PISA server [37].
Surface plasmon resonance
Surface plasmon resonance (BIAcore) was conducted essentially
as previously described [38] utilizing immobilized c-MET
extracellular domain and different concentrations of purified
LMH antibodies to determine KD values.
Flow cytometry
A549 cells were stained for c-MET using 10 mg/ml of each
LMH antibody diluted in 1% HSA/PBS for 1 h at 4uC. A 1:20
secondary anti-mouse IgG-PE (Invitrogen) solution was then
added for 45 min at 4uC. Cells were run on a BD CANTO Flow
Cytometer (BD Biosciences, San Jose, CA) for analysis.
Immunoprecipitation, whole cell lysate and western blot
For agonist and antagonist assays, 50 mg/ml of antibody was
added to serum starved cells for 30 min. Afterward, for antagonist
tests only, 400 ng/ml of HGF was added and cells incubated for a
further 7 min. For c-MET down-regulation assays, 50 mg/ml of
antibody was added and cells incubated for 8 h or 24 h. For
immunoprecipitation (IP) of c-MET, cells were lysed in Triton X-
100 cell lysis buffer and processed as previously described [8],
using either anti-c-MET C-28 antibody coupled to agarose beads
(Santa Cruz) or 5 mg/ml LMH 85 followed by Protein A/G
agarose beads. For whole cell lysate (WCL) analyses, cells were
scraped in the presence of lysis buffer [16Invitrogen LDS sample
buffer, 2.5% (v/v) b-mercaptoethanol, 200 mMN a 3VO4 and
0.4% (v/v) H2O2], aspirated through a syringe, sonicated and
clarified by centrifugation. Western blots were conducted as
previously described [8] using appropriate antibodies for blotting
and infrared detection.
Cell surface biotinylation
A549 cells were plated overnight and washed twice in serum
free medium before 24 h treatments in serum free medium were
added. The next day, antibody was added to the 8 h treatments
using the medium from the dish. At treatment completion, dishes
were washed three times with excess PBS at pH 8.0. Next,
0.5 mg/ml of non-permeating EZ-LinkH Sulfo-NHS-LC-Biotin
(Thermo Scientific) in PBS (pH 8.0) was added and the cells
incubated on a rocking platform at 4uC for 1 h. Cells were then
quenched three times in excess glycine (100 mM). Cells were lysed
and c-MET IPed using anti-c-MET C-28 antibody coupled to
agarose beads as described above. Following SDS-PAGE and
transfer, membranes were probed for biotinylated c-MET using
Streptavidin conjugated to IRDye 680 (LiCor Biosciences) or total
c-MET using rabbit anti-Met (1000–1100) polyclonal antibody
(Abcam) followed by anti-rabbit IRDye800 secondary antibody.
Blots were analysed using infrared detection.
Cell migration assay
For agonist tests, the bottom wells of the 96-well chemotaxis
chambers coated with collagen (Neuro Probe, Gaithersburg, MD)
and filled with different antibody concentrations in RPMI/0.25%
BSA. For antagonist tests, 0.3 pM HGF was mixed with the
antibody. The top of the chamber was filled with 4610
5 SK-OV-3
cells in RPMI/0.25% BSA. After 4 h incubation, the membrane
was recovered and migrated cells fixed in 4% formaldehyde for
1 h, washed in PBS and stained overnight with DeepRed
cytoplasmic stain (Invitrogen). The membranes were scanned
using a LiCor Odyssey Infrared scanner at 700 nm to quantify
stained cells.
xCELLigence
A549 cells were plated in 0.5% FBS media in untreated E-plates
(Roche Diagnostics, Basel, Switzerland) at 5,000 cells per well.
The plate was connected to an xCELLigence RTCA SP
instrument (Roche Diagnostics) within a humidified cell culture
incubator. Treatments were initiated after 21 h incubation. Data
was analysed using the RTCA Software 1.2 program (Roche
Diagnostics). Readings were normalized to the point directly
before antibody addition. All data is presented as the mean
normalized cellular index 6 SEM over time.
Confocal microscopy
For LMH 87 internalization, A549 cells were plated in iBidi 8-
well chamber slides overnight. The next day, cells were washed in
1% HSA/serum free medium before 20 mg/mL of antibody was
added for 45 min at 4uC, followed by an equimolar amount of
anti-mouse IgG labeled with Alexa Fluor 488 (Invitrogen) for
45 min at 4uC. An LMH 85 parallel control was included. For
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labeled with Alexa Fluor 488 overnight using the Alexa Fluor 488
Zenon H Mouse IgG labeling kit (Invitrogen). A549 or LoVo cells
were plated on coverslips overnight and washed in 1% HSA/
serum free medium before 10 mg/ml of labeled antibodies were
added for 45 min at 4uC. To induce internalization in both tests,
serum free medium 37uC was added for 0, 15, 30 or 60 min, after
which cells were fixed in 4% paraformaldehyde, mounted and
scanned using a Nikon C1 confocal microscope equipped with a
606objective.
Xenograft model
U87MG xenograft trials were conducted essentially as previ-
ously described [8]. Briefly, 1610
6 cells were injected into the
ventral left and right flanks of 4- to 6-week old female BALB/c
nude mice. Treatment was initiated when tumor sizes reached 80–
200 mm
3. An intraperitoneal (i.p.) route of administration was
used after which tumor measurement and statistical analyses were
performed as previously described [8]. This project was approved
by the Monash University Animal Ethics Committee.
Supporting Information
Figure S1 LMH 88- induced c-Met degradation and
antagonism of HGF/SF-induced cell migration. (A)
U87MG cells were treated with LMH 88 for the indicated times
and levels of total c-Met determined by immunoblotting. A
sustained decrease in total c-Met levels up to 24 h was observed.
(B) SKOV-3 cells were treated with media alone (basal control;
white), different concentrations of LMH 88 with 3610
210 Mo f
HGF/SF (light grey) or different concentrations of HGF/SF alone
(dark grey) to determine if LMH 88 could inhibit HGF/SF
induced cell migration. LMH 88 inhibited the migratory activity
stimulated by HGF/SF to a degree similar to that for LMH 87.
Data is presented as percentage migration compared to
3610
210 M HGF/SF 6 SD.
(TIF)
Figure S2 LMH 87-induced c-Met down-regulation does
not utilise the presenilin-dependent regulated intra-
membrane proteolysis (PS-RIP) mechanism. A549 cells
were pre-treated with 25 mM of the metalloproteinase inhibitor,
TAPI-2, for 30 min before 50 mg/mL of LMH 87 was added for
8 h. Levels of total c-Met were determined by IP and
immunoblotting. The results show that inhibition of metallopro-
teinase, which is critical to initiate the PS-RIP mechanism, had no
effect on LMH 87-induced c-Met down-regulation.
(TIF)
Figure S3 LMH 80, LMH 81 and LMH 82 all bind the
cell surface by FACS. FACS with isotype control antibody or
the LMH antibodies was conducted on A549, LoVo and U87MG
cell lines. Positive binding of all antibodies confirms that the p170
c-Met is located at the cell surface in cancer cells.
(TIF)
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